262 related articles for article (PubMed ID: 37184093)
1. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
2. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
Hu Y; Narayan A; Xu Y; Wolfe J; Vu D; Trinh T; Kantak C; Ivy SP; Eder JP; Deng Y; LoRusso P; Kim JW; Patel AA
JCO Precis Oncol; 2024 Feb; 8():e2300289. PubMed ID: 38412387
[TBL] [Abstract][Full Text] [Related]
6. Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.
Han X; Tang X; Zhu H; Zhu D; Zhang X; Meng X; Hua Y; Wang Z; Zhang Y; Huang W; Wang L; Yuan S; Zhang P; Gong H; Sun Y; Zhang Y; Liu Z; Dong X; Gai F; Huang Z; Zhu C; Guo J; Wang Z
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600554
[TBL] [Abstract][Full Text] [Related]
7. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
[TBL] [Abstract][Full Text] [Related]
8. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C
BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848
[TBL] [Abstract][Full Text] [Related]
9. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
11. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B; Madison RW; Childress MA; Miller ST; Gjoerup O; Cheng J; Huang RSP; Krainock M; Gupta P; Zou W; Shames DS; Moshkevich S; Ballinger M; Liu MC; Young A; Srivastava MK; Oxnard GR; Socinski MA
Clin Cancer Res; 2023 Nov; 29(22):4596-4605. PubMed ID: 37702716
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
[TBL] [Abstract][Full Text] [Related]
14. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
[TBL] [Abstract][Full Text] [Related]
15. Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.
Ryu WK; Oh S; Lim JH; Lee SJ; Shin HT; Ryu JS
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076922
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.
Duffy MJ
Tumour Biol; 2024; 46(s1):S283-S295. PubMed ID: 37270828
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
19. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
[TBL] [Abstract][Full Text] [Related]
20. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
